Pfizer has been issued a ‘Form 483’ report by the US Food and Drug Administration (FDA) citing eight observations – of which seven are repeat deficiencies – following an inspection from 23 July to 8 August at its former Hospira US manufacturing site in McPherson, Kansas.
According to the 10-page report, Pfizer did not adequately investigate mold contamination results, leading to an undisclosed number of batches...





